Cardiac Insight raises $4.5M and wins FDA approval to launch $20 Cardea Solo seven-day disposable ECG patch

Cardiac Insight raised $4.5 million to commercialize Cardea Solo, a lightweight disposable ECG patch that adheres to the skin for up to seven days and is now FDA-approved and available to healthcare providers; the device can cost as little as $20 and helps detect intermittent cardiac irregularities like atrial fibrillation and tachycardia.

No comments yet.